Adhesion Prevention Products

Our proprietary immunomodulating biopolymers, which are antimicrobial and biodegradable, are designed in the form of thin flexible membrane or highly compressible sponge for various ENT application. 

Antimicrobial Intranasal Splint

Intranasal Splint from Sporogenics, Sporonge Nasal, is a nasal dressing in the form of a microporous and breathable sponge intended to minimize bleeding and to prevent adhesions between the septum and the nasal cavity, and act as an adjunct to aid in the natural healing process post-surgical intervention. The antimicrobial property prevents the formation of biofilm and bacterial infection during the healing process. The first immunomodulating intranasal splint on the market to reduce and ease swelling. The high compressive strength of the intranasal sponge helps to evenly distribute pressure across the nose, significantly reducing the severity of swelling and bruising. This not only aids in a more comfortable recovery but also allows for a quicker return to normalcy.

Sporonge Nasal has been approved by Singapore’s Health Science Authority (HSA) and a US FDA 510K Exempt Class 1 product. 

Adhesion Barrier Membrane for ENT

More than 90% of thyroid cancers are well-differentiated cancers such as papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) which are known to have a good prognosis. Patients with PTC have a 20-year survival rate of > 90%, and FTC has a 10-year survival rate of ~80%. Hence, it is important for thyroid cancer patients to maintain their long-term quality of life. Although surgical resection, thyroidectomy, is the primary treatment for thyroid cancer, more than 50% of patients complain of dysphagia, persistent abnormal sensations or pain, movement disorders and abnormal skin wrinkles due to postsurgical adhesions. To date, there has been no approved adhesion barrier products indicated for ENT. Following our successful animal study, Sporogenics is working closely with US FDA via Q-Submission on pushing the frontier for the development of a novel adhesion barrier membrane suitable for minimally invasive surgical procedures in the field of ENT. Currently, we are actively preparing for the First-in-Human (FIH) trial of this product with our partners. 

Scroll to Top